Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRiBRAVE
2022-001669-11Phase 2Active
- Sponsor
- IFOM
- Start
- Jun 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceralasertib, durvalumab and paclitaxel in triple-negative breast cancer (TNBC) and breast cancer, sponsored by IFOM. Primary endpoint: Progression-free survival. Started Jun 2022; status: active.
02
Drugs
ceralasertibdurvalumabpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2022-001669-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001669-11.